Reason #2: Phase 2 Is Enrolling
In the release, the company said that it is currently in the process of enrolling 32 patients for a Phase 2 clinical trial of onvansertib.
In the Phase 2 trial, patients will be provided with the recommended dose of 60mg/m², in combination with decitabine. Of course, this trial is to further assess the safety, tolerability and efficacy of the treatment.
This is also overwhelmingly exciting news. After all, TROV is moving into mid-stage studies. Should all go well with this trial, the company is likely to move toward a pivotal Phase 3 trial, likely opening the door to the submission of a New Drug Application with the FDA.